drugset / Trial / NCT05279001

A Safety and Tolerability Study of Jaktinib

NCT05279001

Phase 1 Unknown 26 enrolled Suzhou Zelgen Biopharmaceuticals Co.,Ltd
NaSingle-groupOpen-labelTreatment

Summary

This research study is studying a drug called Jaktinib as a possible treatment for Myelofibrosis.

Timeline

Start
2024-07-01
Primary completion
2025-05-31
Completion
2025-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Jaktinib Unknown Oral

Indications